ACADIA PHARMACEUTICALS INC. Operating Income
ACADIA PHARMACEUTICALS INC. (ACAD) reported Operating Income of $37.84 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement
us-gaap:OperatingIncomeLoss · last filed 2026-08-05
- ACADIA PHARMACEUTICALS INC. operating income (loss) for the quarter ending 2026-06-30 was $37.84M, a 16.87% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for the quarter ending 2026-03-31 was -$4.62M, a 123.93% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for the quarter ending 2025-12-31 was $17.39M, a 88.67% decline year-over-year.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for the quarter ending 2025-09-30 was $35.76M, a 12.99% increase year-over-year.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for fiscal 2025 was $104.81M, a 54.59% decline from fiscal 2024.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for fiscal 2024 was $230.79M.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for fiscal 2023 was -$73.38M.
- ACADIA PHARMACEUTICALS INC. operating income (loss) for fiscal 2022 was -$223.60M.
| Period end | Operating Income (Loss) 3 month | Operating Income (Loss) 3 month as first filed | Operating Income (Loss) 6 month | Operating Income (Loss) 6 month as first filed | Operating Income (Loss) 9 month | Operating Income (Loss) 9 month as first filed | Operating Income (Loss) 12 month |
|---|---|---|---|---|---|---|---|
| 2026-06-30 | $37.84M 10-Q · filed 2026-08-05 | $33.22M 10-Q · filed 2026-08-05 | $50.61M derived: sum of 3 quarters · filed 2026-08-05 | $86.37M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2026-03-31 | -$4.62M 10-Q · filed 2026-05-07 | $12.78M derived: sum of 2 quarters · filed 2026-05-07 | $48.53M derived: sum of 3 quarters · filed 2026-05-07 | $80.91M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-12-31 | $17.39M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $53.15M derived: sum of 2 quarters · filed 2026-02-26 | $85.52M derived: sum of 3 quarters · filed 2026-08-05 | $104.81M 10-K · filed 2026-02-26 | |||
| 2025-09-30 | $35.76M 10-Q · filed 2025-11-06 | $68.13M derived: sum of 2 quarters · filed 2026-08-05 | $87.42M 10-Q · filed 2025-11-06 | $240.92M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-06-30 | $32.37M 10-Q · filed 2026-08-05 | $51.66M 10-Q · filed 2026-08-05 | $205.17M derived: sum of 3 quarters · filed 2026-08-05 | $236.81M derived: sum of 4 quarters · filed 2026-08-05 | |||
| 2025-03-31 | $19.29M 10-Q · filed 2026-05-07 | $172.79M derived: sum of 2 quarters · filed 2026-05-07 | $204.44M derived: sum of 3 quarters · filed 2026-05-07 | $234.87M derived: sum of 4 quarters · filed 2026-05-07 | |||
| 2024-12-31 | $153.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $185.15M derived: sum of 2 quarters · filed 2026-02-26 | $215.58M derived: sum of 3 quarters · filed 2026-02-26 | $230.79M 10-K · filed 2026-02-26 | |||
| 2024-09-30 | $31.64M 10-Q · filed 2025-11-06 | $62.08M derived: sum of 2 quarters · filed 2025-11-06 | $77.29M 10-Q · filed 2025-11-06 | $112.23M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-06-30 | $30.44M 10-Q · filed 2025-08-07 | $45.65M 10-Q · filed 2025-08-07 | $80.59M derived: sum of 3 quarters · filed 2026-02-26 | $22.82M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2024-03-31 | $15.21M 10-Q · filed 2025-05-08 | $50.15M derived: sum of 2 quarters · filed 2026-02-26 | -$7.62M derived: sum of 3 quarters · filed 2026-02-26 | -$4.58M derived: sum of 4 quarters · filed 2026-02-26 | |||
| 2023-12-31 | $34.94M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$22.83M derived: sum of 2 quarters · filed 2026-02-26 | -$19.80M derived: sum of 3 quarters · filed 2026-02-26 | -$73.38M 10-K · filed 2026-02-26 | |||
| 2023-09-30 | -$57.78M 10-Q · filed 2024-11-07 | -$54.74M derived: sum of 2 quarters · filed 2024-11-07 | -$108.32M 10-Q · filed 2024-11-07 | -$154.39M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-06-30 | $3.04M 10-Q · filed 2024-08-07 | -$50.55M 10-Q · filed 2024-08-07 | -$96.61M derived: sum of 3 quarters · filed 2025-02-27 | -$127.48M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2023-03-31 | -$53.58M 10-Q · filed 2024-05-09 | -$99.65M derived: sum of 2 quarters · filed 2025-02-27 | -$130.51M derived: sum of 3 quarters · filed 2025-02-27 | -$164.16M derived: sum of 4 quarters · filed 2025-02-27 | |||
| 2022-12-31 | -$46.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$76.93M derived: sum of 2 quarters · filed 2025-02-27 | -$110.58M derived: sum of 3 quarters · filed 2025-02-27 | -$223.60M 10-K · filed 2025-02-27 | |||
| 2022-09-30 | -$30.87M 10-Q · filed 2023-11-03 | -$64.52M derived: sum of 2 quarters · filed 2023-11-03 | -$177.53M 10-Q · filed 2023-11-03 | -$222.19M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-06-30 | -$33.65M 10-Q · filed 2023-08-03 | -$146.67M 10-Q · filed 2023-08-03 | -$191.32M derived: sum of 3 quarters · filed 2024-02-28 | -$206.63M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2022-03-31 | -$113.02M 10-Q · filed 2023-05-08 | -$157.67M derived: sum of 2 quarters · filed 2024-02-28 | -$172.97M derived: sum of 3 quarters · filed 2024-02-28 | -$216.68M derived: sum of 4 quarters · filed 2024-02-28 | |||
| 2021-12-31 | -$44.66M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | -$59.96M derived: sum of 2 quarters · filed 2024-02-28 | -$103.67M derived: sum of 3 quarters · filed 2024-02-28 | -$170.44M 10-K · filed 2024-02-28 | |||
| 2021-09-30 | -$15.30M 10-Q · filed 2022-11-03 | -$59.01M derived: sum of 2 quarters · filed 2022-11-03 | -$125.78M 10-Q · filed 2022-11-03 | -$192.94M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-06-30 | -$43.71M 10-Q · filed 2022-08-09 | -$110.48M 10-Q · filed 2022-08-09 | -$177.64M derived: sum of 3 quarters · filed 2023-02-28 | -$263.54M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2021-03-31 | -$66.77M 10-Q · filed 2022-05-05 | -$133.93M derived: sum of 2 quarters · filed 2023-02-28 | -$219.83M derived: sum of 3 quarters · filed 2023-02-28 | -$263.84M derived: sum of 4 quarters · filed 2023-02-28 | |||
| 2020-12-31 | -$67.16M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | -$153.06M derived: sum of 2 quarters · filed 2023-02-28 | -$197.07M derived: sum of 3 quarters · filed 2023-02-28 | -$286.59M 10-K · filed 2023-02-28 | |||
| 2020-09-30 | -$85.90M 10-Q · filed 2021-11-09 | -$129.91M derived: sum of 2 quarters · filed 2021-11-09 | -$219.42M 10-Q · filed 2021-11-09 | -$275.82M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-06-30 | -$44.01M 10-Q · filed 2021-08-05 | -$133.53M 10-Q · filed 2021-08-05 | -$189.92M derived: sum of 3 quarters · filed 2022-03-01 | -$235.34M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2020-03-31 | -$89.52M 10-Q · filed 2021-05-06 | -$145.91M derived: sum of 2 quarters · filed 2022-03-01 | -$191.34M derived: sum of 3 quarters · filed 2022-03-01 | -$248.43M derived: sum of 4 quarters · filed 2022-03-01 | |||
| 2019-12-31 | -$56.40M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | -$101.82M derived: sum of 2 quarters · filed 2022-03-01 | -$158.91M derived: sum of 3 quarters · filed 2022-03-01 | -$246.54M 10-K · filed 2022-03-01 | |||
| 2019-09-30 | -$45.42M 10-Q · filed 2020-11-04 | -$102.51M derived: sum of 2 quarters · filed 2020-11-04 | -$190.15M 10-Q · filed 2020-11-04 | -$257.42M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-06-30 | -$57.09M 10-Q · filed 2020-08-06 | -$144.72M 10-Q · filed 2020-08-06 | -$212.00M derived: sum of 3 quarters · filed 2021-02-25 | -$273.27M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2019-03-31 | -$87.63M 10-Q · filed 2020-05-08 | -$154.91M derived: sum of 2 quarters · filed 2021-02-25 | -$216.18M derived: sum of 3 quarters · filed 2021-02-25 | -$280.26M derived: sum of 4 quarters · filed 2021-02-25 | |||
| 2018-12-31 | -$67.28M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-25 | -$128.55M derived: sum of 2 quarters · filed 2021-02-25 | -$192.63M derived: sum of 3 quarters · filed 2021-02-25 | -$247.44M 10-K · filed 2021-02-25 | |||
| 2018-09-30 | -$61.27M 10-Q · filed 2019-10-31 | -$125.35M derived: sum of 2 quarters · filed 2019-10-31 | -$180.17M 10-Q · filed 2019-10-31 | -$250.18M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-06-30 | -$64.08M 10-Q · filed 2019-08-01 | -$118.90M 10-Q · filed 2019-08-01 | -$188.91M derived: sum of 3 quarters · filed 2020-02-27 | -$254.55M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2018-03-31 | -$54.82M 10-Q · filed 2019-05-02 | -$124.83M derived: sum of 2 quarters · filed 2020-02-27 | -$190.47M derived: sum of 3 quarters · filed 2020-02-27 | -$258.51M derived: sum of 4 quarters · filed 2020-02-27 | |||
| 2017-12-31 | -$70.01M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | -$135.65M derived: sum of 2 quarters · filed 2020-02-27 | -$203.69M derived: sum of 3 quarters · filed 2020-02-27 | -$292.41M 10-K · filed 2020-02-27 | |||
| 2017-09-30 | -$65.64M 10-Q · filed 2018-11-06 | -$66.31M 10-Q · filed 2017-11-07 | -$133.68M derived: sum of 2 quarters · filed 2018-11-06 | -$222.40M 10-Q · filed 2018-11-06 | -$223.55M 10-Q · filed 2017-11-07 | -$300.63M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-06-30 | -$68.04M 10-Q · filed 2018-08-08 | -$68.43M 10-Q · filed 2017-08-08 | -$156.76M 10-Q · filed 2018-08-08 | -$157.24M 10-Q · filed 2017-08-08 | -$234.99M derived: sum of 3 quarters · filed 2019-02-27 | -$307.39M derived: sum of 4 quarters · filed 2019-02-27 | |
| 2017-03-31 | -$88.72M 10-Q · filed 2018-05-04 | -$88.81M 10-Q · filed 2017-05-09 | -$166.95M derived: sum of 2 quarters · filed 2019-02-27 | -$239.35M derived: sum of 3 quarters · filed 2019-02-27 | -$311.27M derived: sum of 4 quarters · filed 2019-02-27 | ||
| 2016-12-31 | -$78.23M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$150.63M derived: sum of 2 quarters · filed 2019-02-27 | -$222.55M derived: sum of 3 quarters · filed 2019-02-27 | -$272.81M 10-K · filed 2019-02-27 | |||
| 2016-09-30 | -$72.40M 10-Q · filed 2017-11-07 | -$144.32M derived: sum of 2 quarters · filed 2017-11-07 | -$194.58M 10-Q · filed 2017-11-07 | -$240.15M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-06-30 | -$71.92M 10-Q · filed 2017-08-08 | -$122.19M 10-Q · filed 2017-08-08 | -$167.75M derived: sum of 3 quarters · filed 2018-02-27 | -$206.75M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2016-03-31 | -$50.26M 10-Q · filed 2017-05-09 | -$95.83M derived: sum of 2 quarters · filed 2018-02-27 | -$134.82M derived: sum of 3 quarters · filed 2018-02-27 | -$174.32M derived: sum of 4 quarters · filed 2018-02-27 | |||
| 2015-12-31 | -$45.56M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$84.56M derived: sum of 2 quarters · filed 2018-02-27 | -$124.06M derived: sum of 3 quarters · filed 2018-02-27 | -$164.61M 10-K · filed 2018-02-27 | |||
| 2015-09-30 | -$39.00M 10-Q · filed 2016-11-07 | -$78.50M derived: sum of 2 quarters · filed 2016-11-07 | -$119.05M 10-Q · filed 2016-11-07 | -$147.60M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-06-30 | -$39.50M 10-Q · filed 2016-08-04 | -$80.05M 10-Q · filed 2016-08-04 | -$108.60M derived: sum of 3 quarters · filed 2017-02-28 | -$133.60M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2015-03-31 | -$40.55M 10-Q · filed 2016-05-05 | -$69.11M derived: sum of 2 quarters · filed 2017-02-28 | -$94.10M derived: sum of 3 quarters · filed 2017-02-28 | -$115.82M derived: sum of 4 quarters · filed 2017-02-28 | |||
| 2014-12-31 | -$28.55M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$53.55M derived: sum of 2 quarters · filed 2017-02-28 | -$75.27M derived: sum of 3 quarters · filed 2017-02-28 | -$93.23M 10-K · filed 2017-02-28 | |||
| 2014-09-30 | -$24.99M 10-Q · filed 2015-11-05 | -$46.72M derived: sum of 2 quarters · filed 2015-11-05 | -$64.68M 10-Q · filed 2015-11-05 | -$76.84M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-06-30 | -$21.72M 10-Q · filed 2015-08-06 | -$39.68M 10-Q · filed 2015-08-06 | -$51.84M derived: sum of 3 quarters · filed 2016-02-29 | -$62.66M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2014-03-31 | -$17.96M 10-Q · filed 2015-05-07 | -$30.12M derived: sum of 2 quarters · filed 2016-02-29 | -$40.93M derived: sum of 3 quarters · filed 2016-02-29 | -$50.09M derived: sum of 4 quarters · filed 2016-02-29 | |||
| 2013-12-31 | -$12.16M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$22.98M derived: sum of 2 quarters · filed 2016-02-29 | -$32.13M derived: sum of 3 quarters · filed 2016-02-29 | -$38.30M 10-K · filed 2016-02-29 | |||
| 2013-09-30 | -$10.81M 10-Q · filed 2014-11-10 | -$19.97M derived: sum of 2 quarters · filed 2014-11-10 | -$26.13M 10-Q · filed 2014-11-10 | -$32.95M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2013-06-30 | -$9.16M 10-Q · filed 2014-08-05 | -$15.32M 10-Q · filed 2014-08-05 | -$22.14M derived: sum of 3 quarters · filed 2015-02-26 | -$24.55M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2013-03-31 | -$6.16M 10-Q · filed 2014-05-06 | -$12.98M derived: sum of 2 quarters · filed 2015-02-26 | -$15.39M derived: sum of 3 quarters · filed 2015-02-26 | -$20.82M derived: sum of 4 quarters · filed 2015-02-26 | |||
| 2012-12-31 | -$6.82M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-26 | -$9.23M derived: sum of 2 quarters · filed 2015-02-26 | -$14.65M derived: sum of 3 quarters · filed 2015-02-26 | -$20.89M 10-K · filed 2015-02-26 | |||
| 2012-09-30 | -$2.41M 10-Q · filed 2013-11-06 | -$7.84M derived: sum of 2 quarters · filed 2013-11-06 | -$14.07M 10-Q · filed 2013-11-06 | -$19.38M derived: sum of 4 quarters · filed 2014-02-27 | |||
| 2012-06-30 | -$5.43M 10-Q · filed 2013-08-06 | -$11.66M 10-Q · filed 2013-08-06 | -$16.97M derived: sum of 3 quarters · filed 2014-02-27 | -$22.07M derived: sum of 4 quarters · filed 2014-02-27 | |||
| 2012-03-31 | -$6.23M 10-Q · filed 2013-05-07 | -$11.54M derived: sum of 2 quarters · filed 2014-02-27 | -$16.64M derived: sum of 3 quarters · filed 2014-02-27 | -$23.22M derived: sum of 4 quarters · filed 2014-02-27 | |||
| 2011-12-31 | -$5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-27 | -$10.41M derived: sum of 2 quarters · filed 2014-02-27 | -$16.99M derived: sum of 3 quarters · filed 2014-02-27 | -$22.85M 10-K · filed 2014-02-27 | |||
| 2011-09-30 | -$5.09M 10-Q · filed 2012-11-05 | -$11.68M derived: sum of 2 quarters · filed 2012-11-05 | -$17.54M 10-Q · filed 2012-11-05 | $11.59M derived: sum of 4 quarters · filed 2013-03-12 | |||
| 2011-06-30 | -$6.58M 10-Q · filed 2012-08-08 | -$12.45M 10-Q · filed 2012-08-08 | $16.68M derived: sum of 3 quarters · filed 2013-03-12 | $12.44M derived: sum of 4 quarters · filed 2013-03-12 | |||
| 2011-03-31 | -$5.86M 10-Q · filed 2012-05-08 | $23.27M derived: sum of 2 quarters · filed 2013-03-12 | $19.03M derived: sum of 3 quarters · filed 2013-03-12 | $14.73M derived: sum of 4 quarters · filed 2013-03-12 | |||
| 2010-12-31 | $29.13M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-12 | $24.89M derived: sum of 2 quarters · filed 2013-03-12 | $20.59M derived: sum of 3 quarters · filed 2013-03-12 | $15.09M 10-K · filed 2013-03-12 | |||
| 2010-09-30 | -$4.24M 10-Q · filed 2011-11-09 | -$8.54M derived: sum of 2 quarters · filed 2011-11-09 | -$14.04M 10-Q · filed 2011-11-09 | ||||
| 2010-06-30 | -$4.30M 10-Q · filed 2011-08-10 | -$9.79M 10-Q · filed 2011-08-10 | |||||
| 2009-12-31 | -$45.47M 10-K · filed 2012-03-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Viking Therapeutics, Inc. (VKTX) | United States | $4.287B | -8.51 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |